Neuronal nicotinic receptors: A perspective on two decades of drug discovery research

Biochemical Pharmacology

Volumn 74, Issue 8, 2007, Pages 1092-1101

  Arneric, Stephen P ^a   Holladay, Mark ^b   Williams, Michael ^c  

^a Neuromed Pharmaceuticals   (Canada)

^b Ambit Biosciences   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug discovery; nAChR; Nicotine

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 (6 CHLORO 3 PYRIDAZINYL) 3,8 DIAZABICYCLO[3.2.1]OCTANE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; 4 OH GTS 21; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; ABT 894; ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST; ALTINICLINE; AMFEBUTAMONE; ANALGESIC AGENT; AZD 3480; DIZOCILPINE; EPIBATIDINE; GBR 129 09; ISPRONICLINE; LIDOCAINE ETHOBROMIDE; MEM 3454; MEM 63908; MORPHINE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; PNU 120596; PNU 282987; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; SSR 180711; TC 2216; TC 2403; TC 2696; TC 5619; UB 165; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE;

ACADEMIC ACHIEVEMENT; ADDICTION; ALZHEIMER DISEASE; ANXIETY; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COGNITION; DEPRESSION; DRUG FORMULATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ELECTROPHYSIOLOGY; FROG; HUMAN; MEDICAL RESEARCH; MEDICINAL PLANT; MONOTHERAPY; NERVE CELL; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING CESSATION; ULCERATIVE COLITIS;

ANIMALS; COGNITION; DRUG DESIGN; DRUG INDUSTRY; HUMANS; NEURONS; PAIN; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SMOKING CESSATION;

EID: 34548679635     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.06.033     Document Type: Article

References (87)

1. Nachmansohn D. Chemical factors controlling nerve activity. Science 154 (1961) 1962-1968
2. Stroud R.M., and Finer-Moore J. Acetylcholine receptor, structure, function and evolution. Ann Rev Cell Biol 1 (1985) 217-351
3. Changeux J.-P., and Edlestein S.J. Nicotinic acetylcholine receptors: from molecular biology to cognition (2005), Odile Jacob, New York
4. Bartus R.T., Dean R.L., Beer B., and Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
5. Coyle J.T., Price D.L., and DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219 (1983) 1184-1190
6. Babic T., Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiat 67 (1999) 558-1558
7. Bonner T.I., Buckley N.J., Young A.C., and Brann M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science 237 (1987) 527-532
8. Katz B., and Thesleff S. A study of 'desensitization' produced by acetylcholine at the motor end plate. J Physiol (Lond) 138 (1967) 63-80
9. Lippiello P.M., and Fernades K.G. The binding of l-[3H]nicotine to a single class of high affinity sites in rat brain membranes. Mol Pharmacol 29 (1986) 448-454
10. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 3 (2002) 102-114
11. Dani J.A., and Bertrand D. Ann Rev Pharmacol Toxicol 47 (2007) 699-729
12. Ballivet M., Patrick J., Lee J., and Heinemann S. Molecular cloning of cDNA for the gamma subunit of the Torpedo acetylcholine receptor. Proc Natl Acad Sci USA 79 (1981) 4466-4470
13. Heinemann S., Merlie S.J., and Lindstrom J. Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera. Naturem 274 (1978) 65-68
14. Patrick J. Drug abuse res. II. Structure, function and expression. NIDA Res Monograph 126 (1992) 9-18
15. Buisson B., and Bertrand D. Chronic exposure to nicotine upregulates human α4β2 nicotinic acetylcholine receptor function. J Neurosci 21 (2001) 1819-1829
16. Gotti C., Fornasari D., and Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol 53 (1997) 199-237
17. McGehee D.S., and Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Ann Rev Physiol 51 (1995) 521-546
18. Smit A.B., Syed N.I., Schaap D., van Minnen J., Klumperman J., Kits K.S., et al. A glia-derived acetylcholine-binding protein that modulates synaptic transmission. Nature 411 (2001) 261-268
19. Gotti C., Moretti M., Gaimarri A., Zanardi A., Clementi F., and Zoli M. Heterogenity and complexity of native brain neuronal nicotinic receptors. Biochem. Pharmacol. 74 (2007) 1102-1111
20. Dunbar G., Boeijinga P.H., Demazieres A., Cisterni C., Kuchibhatla R., Wesnes K., et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 191 (2007) 919-929
21. Schneider J.S., Tinker J.P., Van Velson M., Menzaghi F., and Lloyd G.K. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J Pharmacol Exp Ther 290 (1999) 731-739
22. Schneider J.S., Tinker J.P., Menzaghi F., and Lloyd G.K. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 306 (2003) 401-406
23. Stauderman K.A., Mahaffy L.S., Akong M., Veliçelebi G., Chavez-Noriega L.E., Crona J.H., et al. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations α2β4, α3β4 and α4β4 stably expressed in HEK293 cells. J Pharmacol Exp Ther 284 (1998) 777-789
24. Holladay M.W., Dart M.J., and Lynch J.K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 40 (1997) 4169-4194
25. Shieh C.C., Trumbull J.D., Sarthy J.F., McKenna D.G., Parihar A.S., Zhang X.-F., et al. Automated Parallel Oocyte Electrophysiology Test Station (POETS): a screening platform for identification of ligand-gated ion channel modulators. Assay Drug Develop Technol 1 (2003) 655-663
26. Kem W.R. The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 11 (2000) 169-181
27. Uteshev V.V., Meyer E.M., and Papke R.L. Regulation of neuronal function by choline and 4OH-GTS-21 through α7 nicotinic receptors. J Neurophysiol 89 (2003) 179-1806
28. Ghelardini C., Galeotti N., Giuliani F., Barlocco D., and Bartolini A. Antinociceptive profile of the new nicotinic agonist DBO-83. Drug Dev Res 40 (1997) 251-258
29. Ghelardini C., Galeotti N., Giuliani F., Barlocco D., and Bartolini A. Antiamnesic activity of the nicotinic agonist DBO-83 in mice. Drug Dev Res 45 (1998) 45-51
30. Sharples C.G.V., Kaiser S., Soliakov L., Marks M.J., Collins A.C., Washburn M., et al. UB-165: a novel nicotinic agonist with subtype selectivity implicates the α4β2 subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 20 (2000) 2783-2791
31. Spande T.F., Garraffo H.M., Edwards M.W., Yeh H.J.C., Pannell L., and Daly J.W. A new class of alkaloids from a dendrobatid poison frog: A structure for alkaloid 251F. J Am Chem Soc 114 (1992) 3475-3478
32. Lloyd G.K., and Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292 (2000) 461-467
33. Breining S.R., Mazurov A.A., and Miller S.H. Neuronal nicotinic acetylcholine receptor modulators: recent advances and therapeutic potential. Ann Rep Med Chem 40 (2005) 3-16
34. Broad L.M., Sher E., Astles P.C., Zwart R., and O'Neill M.J. Selective α7 nicotinic receptor agents for the treatment of neuropsychiatric diseases. Drugs Fut 32 (2007) 161-170
35. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist, varenicline, an effective smoking cessation aid. Neuropharmacology 52 (2007) 985-994
36. Jorenby, DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al., for the Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. A randomized controlled trial. J Am Med Assoc 2006;296:56-63.
37. Sahakian B., Jones G., Levy R., Gray J., and Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiat 154 (1989) 797-800
38. Newhouse P., Sunderland T., and Tariot P. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95 (1998) 171-175
39. Arneric S.P., Sullivan J.P., Briggs C., Anderson D.J., Cadman E.D., Adams P., et al. ABT 418: A novel cholinergic ligand with cognition enhancing and anxiolytic activity. I. In vitro activity. J Pharmacol Exp Ther 270 (1994) 310-318
40. Decker M., Brioni J., Sullivan J.P., Buckley M., Raszkiewicz J.L., Kang C.-H., et al. ABT 418: A novel cholinergic ligand with cognition enhancing and anxiolytic activity. II. In vivo activity. J Pharmacol Exp Ther 270 (1994) 319-328
41. Potter A., Corwin J., Lang J., Piasecki M., Lenox R., and Newhouse P.A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology 142 (1999) 334-342
42. Wilens T.E., Biederman J., Spencer T.J., Bostic J., Prince J., Monuteaux M.C., et al. A cholinergic agonist for attention deficit hyperactivity disorder. A pilot controlled clinical trial of ABT-418 in adults. Am J Psychiatr 156 (1999) 1931-1937
43. Sullivan J.P., Donnelly- Roberts D., Briggs C.A., Anderson D.J., Gopalkrishnan M., Xue I.C., et al. ABT 089 [2-methyl-3- (2-(S)-pyrrolidinylmethoxy) pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 283 (1997) 235-246
44. Wilens T.E., Verlinden M.H., Adler L.A., Wozniak P.J., and West S.A. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 59 (2006) 1065-1070
45. Zamani M.R., and Allen Y.S. Nicotine, its interaction with β-amyloid protein: a short review. Biol Psychiatr 49 (2001) 221-232
46. Goedert M., and Spillantini M.G. A century of Alzheimer's disease. Science 314 (2006) 777-781
47. 1-42 binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors. J Neurochem 75 (2000) 1155-1161
48. Liu Q.-S., Kawai H., and Berg D.K. β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 98 (2001) 4734-4739
49. Dineley K.T., Bell K.A., Bui D., and Sweatt J.D. β-Amyloid peptide activates α7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277 (2002) 25056-25061
50. Dineley K.T., Xia X., Bui D., Sweatt J.D., and Zheng H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of α7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precusor proteins. J Biol Chem 277 (2002) 22768-22780
51. Wang H.-Y., Li W., Benndetti N.J., and Lee D.H.S. α7 Nicotinic acetylcholine receptors mediate β-amyloid peptide-induced tau protein phosphorylation. J Biol Chem 278 (2003) 31547-31553
52. Henningfield J.E., and Heishman S.J. Behavioral toxicology of nicotine. In: Benowitz N.L. (Ed). Nicotine safety and toxicity (1998), Oxford University Press, New York 133-146
53. Goff D.C., Henderson D.C., and Amico E. Cigarette smoking in schizophrenia: relationship to pschopathology and medication side effects. Am J Psychiatr 149 (1992) 1189-1194
54. Adler L.E., Hoofer L.D., Wiser A., and Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150 (1993) 1856-1861
55. Leonard S., Adler L.E., Olincy A., Breese C.R., Gault J., Ross R.G., et al. The role of nicotine and nicotinic receptors in psychotherapy. In: Arneric S.P., and Brioni J. (Eds). Neuronal Nicotinic Receptors; Pharmacology and Therapeutic Opportunities (1998), Wiley-Liss, NY 307-322
56. Leonard S., Breese C., Adams C., Benhammou K., Gault J., Stevens K., et al. Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur J Pharm 393 (2000) 237-242
57. 7 receptors. Br J Pharmacol 142 (2004) 843-850
58. Woodruff-Pak D.S., and Gould T.J. Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. Behav Cognitive Neurosci Rev 1 (2002) 5-20
59. Freedman R., Adams C.E., Adler L.E., Bickford P.C., Gault J., Harris J., et al. Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia. Am J Med Genet 97 (2000) 58-64
60. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., et al. Promoter variants in the α7 nicotinic receptor subunit gene are associated with an inhibitory deficit in schizophrenia. Arch Gen Psychiatr 59 (2002) 1085-1096
61. Martin L.F., and Freedman R. Schizophrenia and the α7 nicotinic acetylcholine receptor. Int Rev Neurobiol 78 (2007) 225-246
62. Marder S.R., and Fenton W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS Initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72 (2004) 5-10
63. Green M.F. Stimulating the development of drug treatments to improve cognition in schizophrenia. Ann Rev Clin Psychol 3 (2007) 159-180
64. Levin E.D., Bettergowda C., Blosser J., and Gordon J. AR-R 17779, an α7 nicotinic agonist improves learning and memory in rats. Behav Pharmacol 10 (1999) 675-680
65. Hajós M., Hurst R.S., Hoffmann W.E., Krause M., Wall T.M., Higdon N.R., et al. The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312 (2005) 1213-1222
66. Pichat P., Bergis O.E., Terranova J.-P., Urani A., Duarte C., Santucci, et al. SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of active against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32 (2007) 1-16
67. Boess F.G., De Vry J., Erb C., Flessner T., Hendrix M., Luithle J., et al. The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321 (2007) 716-725
68. Huang M., Li Z., Prus A.J., Sai J., Callahan P.M., and Meltzer H.Y. The nicotinic alpha-7 receptor partial agonist MEM 3454 increases dopamine and acetylcholine release in rat media prefrontal cortex and hippocampus alone and in combination with risperidone. Neuropsychopharmacology 31 (2006) S185 #126
69. Toyooka N., Fukutome A., Shinoda H., and Nemoto H. Total synthesis of the antipode of alkaloid 205 B. Angew Chem Int Ed Engl 42 (2003) 3808-3810
70. Mihalak K.B., Carroll F.I., and Luetje C.W. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 70 (2006) 801-805
71. 7-nicotinic acetylcholine receptors. Neuropharmacology 52 (2007) 387-394
72. Davis L., Pollock L.J., and Stone T.T. Visceral pain. Surg Gynecol Obstet 55 (1932) 418-427
73. Daly J.W., Garraffo H.M., Spande T.F., Decker M.W., Sullivan J.P., and Williams M. Alkaloids from frog skin: the discovery of epibatidine, the potential for discovery of novel non-opioid analgesics. Nat Prod Rep 17 (2000) 131-135
74. Bradley D. Frog venom cocktail yields a one-handed painkiller. Science 261 (1993) 1117
75. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D.D., Puttfarcken P.S., et al. Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 289 (1998) 77-81
76. Simon P. Senorita with a necklace of tears. You're The One Warner Bros. Records CD 9 (2000) 47844-47852
77. Pajouhesh H., and Lenz G.R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2 (2005) 541-553
78. Dwoskin L.P., and Crooks P.A. Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery. J Pharmacol Exp Ther 298 (2001) 395-402
79. Changeux J.-P., and Edelstein S.J. Allosteric mechanism in normal and pathological nicotinic acetylcholine receptors. Curr Opin Neurobiol 11 (2001) 369-377
80. Marino M.J., Davis R.A., Meltzer H., Knutsen L.S.J., and Williams M. Schizophrenia. In: Williams M. (Ed). Comprehensive medicinal chemistry. 2nd ed. vol. 6 (2007), Elsevier, Oxford 17-44
81. McIntosh J.M., Santos A.D., and Olivera B.M. Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes. Ann Rev Biochem 68 (1999) 59-88
82. Szasz B.K., Vizi E.S., and Kiss J.P. Nicotinic acetylcholine receptor antagonistic property of the selective dopamine uptake blocker, GBR-12909 in rat hippocampal slices. Neuroscience 145 (2007) 344-349
83. Santos M.D., Alkondon M., Pereira E.F., Aracava Y., Eisenberg H.M., Maelicke A., et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61 (2002) 1222-1234
84. Hurst R.S., Hajós M., Raggenbass M., Wall T.M., Higdon N.R., Lawson J.A., et al. A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neuroscience 25 (2005) 4396-4405
85. Broad L.M., Zwart R., Pearson K.H., Lee M., Wallace L., McPhie G.I., et al. Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther 318 (2006) 1108-1117
86. Ji J, Li T, Mortell KH, Schrimpf MR, Nersesian DL. New fused bicyclohetercyle substituted quinuclidine derivatives are a7 nicotinic acetylcholine receptor modulators. WO20070187380A2
87. Steensland P., Simms J.A., Holgate J., Richards J.K., and Bartlett S.E. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 104 (2007) 12518-12523